It’s time to rethink clinical trials in a post-pandemic world

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Becky Stephens is more than willing to go to great lengths for a miracle. With a diagnosis of stage 4 colon cancer and chemo treatments that weren’t working, she was desperate for hope—and found it in a clinical trial. 

So, the mother of three started making the often, four-hour round-trip trek from Santa Rosa to UCSF Medical Center every two weeks to participate. But the travel was tough. Aside from the cancer treatment leaving her exhausted, the long car trips were wearing on her. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation
Table of Contents

YOU MAY BE INTERESTED IN

By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it.  To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login